Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 62.1 TWD 0.16% Market Closed
Market Cap: 10.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

EV/FCFF
Enterprise Value to FCFF

-7.9
Current
-7.4
Median
4.1
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-7.9
=
Enterprise Value
10.9B TWD
/
FCFF
-1.4B TWD
All Countries
Close
Market Cap EV/FCFF
KY
Tanvex BioPharma Inc
TWSE:6541
10.2B TWD -7.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -238 493.8
US
Abbvie Inc
NYSE:ABBV
314.6B USD 23.4
US
Amgen Inc
NASDAQ:AMGN
141.2B USD 30.1
US
Gilead Sciences Inc
NASDAQ:GILD
117.3B USD 11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD -72.3
US
Epizyme Inc
F:EPE
94.1B EUR -470.3
AU
CSL Ltd
ASX:CSL
136.4B AUD 62.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD 21.5
US
Seagen Inc
F:SGT
39.3B EUR -56.7
NL
argenx SE
XBRU:ARGX
36.2B EUR -106.6
 
KY
Tanvex BioPharma Inc
TWSE:6541
Average EV/FCFF: 29.8
Negative Multiple: -7.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -238 493.8
US
Abbvie Inc
NYSE:ABBV
23.4
US
Amgen Inc
NASDAQ:AMGN
30.1
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -72.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -470.3
AU
CSL Ltd
ASX:CSL
62.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.7
NL
argenx SE
XBRU:ARGX
Negative Multiple: -106.6

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More